SCENESSE Canada Approval: Regulatory Momentum Collides With Unresolved HTA Rejection Risk

Health Canada Approves SCENESSE® for Erythropoietic Protoporphyria

Clinuvel Pharmaceuticals Limited announced that Health Canada has granted a Notice of Compliance (NOC) for its novel drug SCENESSE® (afamelanotide). This approval allows SCENESSE® to be marketed in Canada for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP), a rare metabolic disorder affecting 5,000-10,000 individuals globally, including approximately 1 in 140,000 in Canada. SCENESSE® is the world's first systemic photoprotective drug for EPP, with previous marketing authorizations in Europe (2014), the U.S. (2019), and Australia (2020). Over 21,000 doses have been administered worldwide, demonstrating a proven long-term safety profile.

• Canadian Regulatory Milestone and Global Context: Health Canada's Notice of Compliance for SCENESSE® marks a significant regulatory achievement for Clinuvel, enabling the drug's commercial distribution in Canada. This approval expands SCENESSE®'s global reach, following successful marketing authorizations in Europe (2014), the U.S.A. (2019), and Australia (2020), solidifying its position as the only approved treatment for EPP worldwide.
• Drug Profile, Mechanism of Action, and Safety: SCENESSE® (afamelanotide) is a peptide therapy containing 16mg of afamelanotide, an analogue of a naturally occurring hormone. Its mechanism involves stimulating melanin production in the skin, providing a photoprotective effect, and acting as a strong antioxidant. The drug has demonstrated a consistent and positive long-term safety profile over two decades, with over 21,000 doses administered to EPP patients globally.
• Addressing a Rare Disease with Unmet Need: Erythropoietic protoporphyria (EPP) is a rare metabolic disorder causing severe phototoxic reactions and burns from light exposure. It impacts an estimated 5,000-10,000 individuals worldwide, including approximately 1 in 140,000 Canadians. SCENESSE® offers a crucial therapeutic option for these patients, who previously lacked approved treatments, addressing a significant unmet medical need with a proven systemic photoprotective solution.

Addressing the Significant Unmet Need in EPP

Current treatment approaches for erythropoietic protoporphyria (EPP) are constrained by a combination of limited therapeutic options, methodological gaps in the evidence base, and unresolved disease biology. While afamelanotide represents a meaningful advance as the only approved therapy, its availability leaves critical patient populations and clinical needs unaddressed.

• Restricted approval scope of afamelanotide: As the sole approved treatment for EPP, afamelanotide effectively prevents phototoxic reactions and improves quality of life; however, it is only indicated for adult patients, leaving children and adolescents without any approved treatment option.

• Failure to address underlying disease mechanism: Afamelanotide provides photoprotection through dual photoprotective and anti-inflammatory effects but does not target the underlying pathophysiology of EPP, representing a fundamental limitation in disease management.

• Insufficient evidence base for alternative therapies: A systematic review of 25 studies (454 patients) found that available data were insufficient to prove efficacy for any EPP treatments evaluated prior to afamelanotide's approval. Only 5 of the 25 studies were randomized controlled trials; the remainder were open-label, uncontrolled studies or retrospective case reports — many published in the 1970s and lacking standardized efficacy criteria.

• Demonstrated inefficacy of historically used agents: Four of five well-designed studies indicated a lack of efficacy for beta-carotene, NAC, and vitamin C, with beta-carotene results being strongly contradictory and efficacy inversely correlated with study quality.

• Non-comparability of investigational therapies: Dersimelagon, bitopertin, and cimetidine are each being evaluated against placebo or baseline rather than against afamelanotide, making cross-trial comparisons impossible. Differences in outcome measures and patient populations further preclude direct comparison, leaving the relative benefit of emerging agents undefined.

• Incomplete characterization of pipeline agents: The safety and efficacy profiles of dersimelagon and bitopertin require further characterization. Generating head-to-head data versus afamelanotide will be essential to inform regulatory decision-making and ensure meaningful patient access upon approval.

• Methodological and ethical challenges in trial design: Several investigational treatment protocols for EPP have been identified as presenting methodologically challenging aspects and ethical concerns, adding complexity to the development of robust clinical evidence in this rare disease setting.

SCENESSE®'s Long-Term Safety Profile for EPP

Published safety and tolerability data for afamelanotide across its studied indications present a consistently positive profile, with the most robust real-world evidence drawn from a postauthorisation safety study (PASS) conducted in Germany. This 2025 study enrolled 200 EPP patients and demonstrated that the short- and long-term safety and benefit-risk profile of afamelanotide under real-world conditions is consistent with the positive safety profile established in clinical trials. Notably, the safety profile in patients over 70 years of age was consistent with the overall patient population, underscoring tolerability across age groups. A retention rate of 91.0% among patients who initiated treatment further reflects the drug's tolerability in routine clinical practice. EPP patients also reported a statistically significant improvement in quality of life compared with baseline values (p < 0.0001), affirming the ongoing clinical benefit of the treatment.

Earlier clinical evidence from a 2010 EPP study provided important mechanistic and tolerability insights. In five EPP patients receiving a sustained-release subcutaneous implant of 20 mg afamelanotide administered twice at a 60-day interval, only two low-grade pain episodes were recorded, and no phototoxic events were observed beyond Day 4 of treatment. From Day 30 to Day 120, tolerance to photoprovocation increased significantly compared with baseline (P = 0.007), and skin melanin density was significantly elevated above baseline (P = 0.004). Tolerance to natural sunlight extended to up to 24 times longer than prior to therapy — a clinically meaningful finding for a patient population whose daily functioning is severely constrained by light sensitivity. The authors acknowledged the limited sample size and open-label design as factors necessitating confirmation through larger-scale trials.

Beyond EPP, afamelanotide has been investigated across a spectrum of photodermatological indications, including vitiligo, polymorphic light eruption, solar urticaria, and prevention of actinic keratoses in organ transplant recipients, with phase II and III trials conducted in both Europe and the United States. In a 2011 solar urticaria study (n=5), a single 16 mg subcutaneous implant produced a significant increase in mean melanin density from Day 7, peaking at Day 15 and remaining elevated at Day 60 (P = 0.03, 0.01, and 0.02 versus baseline, respectively). A significant reduction in wheal area was observed across responding wavelengths from 300 to 600 nm at 60 days post-implant (P = 0.049 vs. baseline), alongside a greater than twofold increase in minimum urticarial dose (P = 0.058 vs. baseline). Taken together, the available data across indications support a well-tolerated safety profile for afamelanotide, with SCENESSE® (afamelanotide 16 mg) having achieved regulatory approval as the first authorised treatment for EPP, initially in Italy and Switzerland.

How SCENESSE® Transforms EPP Treatment Guidelines

Erythropoietic protoporphyria (EPP) is characterized by painful and debilitating phototoxic reactions in cutaneous blood vessels upon exposure to visible light. Afamelanotide (SCENESSE®) currently represents the only approved pharmacotherapy for EPP, demonstrating clinically meaningful improvements in photosensitivity outcomes and patient quality of life. However, important therapeutic gaps remain, particularly for pediatric populations and disease-modifying intervention.

• Afamelanotide is the sole approved treatment for EPP, effectively preventing phototoxic pain and prolonging tolerable sun exposure time, though it does not address the underlying disease mechanism and is approved only for adult patients — leaving children and adolescents without a pharmacological treatment option.

• Real-world outcomes data support robust clinical benefit: an Austrian EPP cohort study (2023; n=20) demonstrated that EPP quality-of-life scores increased from a median of 11.11 (IQR 3.03–19.44) at baseline to 79.17 (IQR 75.00–97.22) under afamelanotide therapy, with phototoxic burn tolerance time (PBTT) increasing from a median of 15 minutes (IQR 10–25) to 250 minutes (IQR 120–300).

• Reduction in phototoxic reaction frequency was substantial: 88% of patients experienced phototoxic reactions prior to therapy, compared to only 33% while on afamelanotide, with treatment-emergent side effects characterized as mild and transient.

• Two investigational therapies — dersimelagon and bitopertin — are currently under clinical investigation and may offer additional benefits, including potential treatment options for pediatric patients and prevention of certain EPP-associated disease complications.

• Available trial data indicate preliminary treatment effects for both dersimelagon and bitopertin versus placebo; however, their safety and efficacy profiles require further characterization, and comparative data against afamelanotide will be critical to inform relative positioning and post-approval patient access decisions.

Systemic Photoprotection Expands Global Reach for EPP

The recent Health Canada approval of SCENESSE® (afamelanotide) for erythropoietic protoporphyria (EPP) marks a pivotal moment for patients in Canada living with this debilitating rare disease. EPP is characterized by extreme sensitivity to light, leading to severe pain and skin damage upon sun exposure, profoundly impacting patients' daily lives and quality of life. Afamelanotide offers a groundbreaking systemic solution, acting as an analog of alpha-melanocyte stimulating hormone to boost melanin production, thereby increasing the skin's natural photoprotection.

This authorization is not an isolated event but rather a continuation of a global regulatory success story, with SCENESSE® already approved in Europe, the U.S., and Australia. This broad international acceptance, coupled with a proven long-term safety profile from over 21,000 administered doses, underscores the drug's robust clinical evidence and its significant benefit-risk profile. For Clinuvel, this expands their commercial footprint into another key market, reinforcing their leadership in developing innovative therapies for rare dermatological conditions.

However, the path forward is not without its considerations:

• While real-world data has been positive, initial clinical trials for EPP were conducted in limited patient populations and open-label designs, suggesting the ongoing importance of collecting real-world evidence to further solidify long-term outcomes.

• The market faces the challenge of unregulated analogs and counterfeit products, which could pose patient safety risks and dilute the legitimate drug's market integrity.

• Despite approval, the ultra-rare nature of EPP means that patient identification and market access strategies will remain critical for successful commercialization.

Ultimately, this approval represents a significant step towards improving the lives of EPP patients by providing a much-needed systemic photoprotective option, while also highlighting the strategic importance of rare disease drug development and global market expansion.